Trial Condition(s):

Atrial Fibrillation, Venous Thromboembolism, Pulmonary Embolism

Verification of XAPPORT: a decision support app for physicians used for patients anticoagulated with rivaroxaban in terms of anticoagulation Management in elective surgery: verification process of medical decision algorithm (VeriXAPPORT)

Bayer Identifier:

18903

ClinicalTrials.gov Identifier:

NCT02900404

EudraCT Number:

Not Available

Terminated/Withdrawn

Trial Purpose

This study shall determine whether XAPPORT – a mobile device app based on different guidelines, the summary of product characteristics of rivaroxaban, and clinical facts and practice – provides adequate guidance to physicians attending patients undergoing elective surgery, who have to interrupt treatment with rivaroxaban for surgery, in deciding how to approach the pre- and postoperative management of anticoagulation.

Inclusion Criteria
- Female or male patient ≥18 years who provided signed and dated informed consent to the use of their medical data
               - Patient was treated with rivaroxaban before and after surgery because of non-valvular atrial fibrillation (NVAF) or venous thromboembolism/pulmonary embolism (VTE/PE)
              - Elective surgery in a department of General Surgery or Orthopedics / Trauma Surgery was performed within the last 12 months before study start
             - The patient has been discharged from hospital 
             - Patient’s medical records are available for data entry
Exclusion Criteria
- Patient participated in an interventional drug study within 3 months prior to the surgery and discharge from hospital

Trial Summary

Enrollment Goal
0
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Locations
Status
LocationsStatus

Trial Design